Using multiple in vivo and in vitro models, Zhang and colleagues reported that CAFs promote resistance to antiandrogen therapy and identified NRG1 as a key secreted mediator acting through HER3 activation in tumor cells. This evidence concerns the gene ERBB3 and neoplasm.